Abbott’s Humira tarnished by patient resistance

Posted April 12 at 12:50 p.m.

From Bloomberg News | Abbott Laboratories’ Humira spurred resistance in more than a quarter of patients taking the rheumatoid arthritis drug in a study, a finding that may weaken demand for the company’s top-selling medicine. Get the full story>>

Read more about the topics in this post: , ,

Companies in this article

Abbott Labs

Read more about this company »

Leave a comment

Required. Your email address will not be published.